Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew J Muir

Showing results (171-180 of 187) with videos related to

Pageof 19
Sort By:
Hepatology (Baltimore, Md.)|April 14, 2011
Racial differences in hepatitis C treatment eligibilityMichael T Melia, Andrew J Muir, Jonathan McCone, et al.
Digestive Diseases and Sciences|May 1, 2012
The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infectionPaul J Clark, Alexander J Thompson, Qianqian Zhu, et al.
The New England Journal of Medicine|November 17, 2015
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated CirrhosisMichael P Curry, Jacqueline G O'Leary, Natalie Bzowej, et al.
Journal of Hepatology|December 24, 2013
Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null responseJohn M Vierling, Mitchell Davis, Steven Flamm, et al.
The New England Journal of Medicine|June 24, 2011
Telaprevir for previously untreated chronic hepatitis C virus infectionIra M Jacobson, John G McHutchison, Geoffrey Dusheiko, et al.
JAMA|May 6, 2015
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosisAndrew J Muir, Fred Poordad, Jacob Lalezari, et al.
Gastroenterology|July 11, 2018
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic SteatohepatitisStephen A Harrison, Manal F Abdelmalek, Stephen Caldwell, et al.
The New England Journal of Medicine|July 24, 2009
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infectionJohn G McHutchison, Eric J Lawitz, Mitchell L Shiffman, et al.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infectionNezam Afdhal, Stefan Zeuzem, Paul Kwo, et al.
JAMA|May 6, 2015
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infectionFred Poordad, William Sievert, Lindsay Mollison, et al.
Pageof 19

Showing results (171-180 of 187) with videos related to

Sort By:
Pageof 19
Hepatology (Baltimore, Md.)|April 14, 2011
Racial differences in hepatitis C treatment eligibilityMichael T Melia, Andrew J Muir, Jonathan McCone, et al.
Digestive Diseases and Sciences|May 1, 2012
The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infectionPaul J Clark, Alexander J Thompson, Qianqian Zhu, et al.
The New England Journal of Medicine|November 17, 2015
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated CirrhosisMichael P Curry, Jacqueline G O'Leary, Natalie Bzowej, et al.
Journal of Hepatology|December 24, 2013
Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null responseJohn M Vierling, Mitchell Davis, Steven Flamm, et al.
The New England Journal of Medicine|June 24, 2011
Telaprevir for previously untreated chronic hepatitis C virus infectionIra M Jacobson, John G McHutchison, Geoffrey Dusheiko, et al.
JAMA|May 6, 2015
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosisAndrew J Muir, Fred Poordad, Jacob Lalezari, et al.
Gastroenterology|July 11, 2018
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic SteatohepatitisStephen A Harrison, Manal F Abdelmalek, Stephen Caldwell, et al.
The New England Journal of Medicine|July 24, 2009
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infectionJohn G McHutchison, Eric J Lawitz, Mitchell L Shiffman, et al.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infectionNezam Afdhal, Stefan Zeuzem, Paul Kwo, et al.
JAMA|May 6, 2015
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infectionFred Poordad, William Sievert, Lindsay Mollison, et al.
Pageof 19